115th CONGRESS 2d Session |
To amend the Controlled Substances Act relating to controlled substance analogues.
June 7, 2018
Mr. Thornberry introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
To amend the Controlled Substances Act relating to controlled substance analogues.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
This Act may be cited as the “Synthetic Abuse and Labeling of Toxic Substances Act of 2018” or the “SALTS Act”.
SEC. 2. Controlled substance analogues.
Section 203 of the Controlled Substances Act (21 U.S.C. 813) is amended—
(1) by striking “A controlled” and inserting “(a) In general.—A controlled”; and
(2) by adding at the end the following:
“(b) Determination.—In determining whether a controlled substance analogue was intended for human consumption under subsection (a), the following factors may be considered, along with any other relevant factors:
“(1) The marketing, advertising, and labeling of the substance.
“(2) The known efficacy or usefulness of the substance for the marketed, advertised or labeled purpose.
“(3) The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold.
“(4) The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance.
“(5) Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means.
“(6) Any controlled substance analogue that is manufactured, formulated, sold, distributed, or marketed with the intent to avoid the provisions of existing drug laws.
“(c) Limitation.—For purposes of this section, evidence that a substance was not marketed, advertised, or labeled for human consumption, by itself, shall not be sufficient to establish that the substance was not intended for human consumption.”.